万古霉素治疗药物浓度监测队列研究

发布时间：2018-03-26 15:36

本文选题：万古霉素　切入点：治疗药物浓度监测　出处：《中国感染与化疗杂志》2015年05期

【摘要】：目的了解革兰阳性菌感染患者根据治疗药物浓度监测结果调整万古霉素给药方案的有效性和安全性。方法收集复旦大学附属华山医院2005年1月—2014年9月进行万古霉素治疗药物浓度监测(TDM)的住院患者128例,分为治疗方案调整组和未调整组进行TDM数据、万古霉素疗效、安全性分析,并建立Cox模型和生存曲线。结果调整组万古霉素日剂量和血药谷浓度高于未调整组,细菌学疗效和综合疗效也优于未调整组。Cox比例风险模型提示调整给药方案是疗效的保护因素。未发现安全性相关危险因素。结论根据TDM结果调整感染患者万古霉素给药方案,对于提高革兰阳性菌感染患者疗效有重要意义。
[Abstract]:Objective to investigate the efficacy and safety of vancomycin regimen in patients with Gram-positive bacilli infection according to the results of drug concentration monitoring. Methods from January 2005 to September 2014, Huashan Hospital affiliated to Fudan University was collected. 128 inpatients with TDM were treated with TDM. The patients were divided into two groups: control group and unadjusted group for TDM data. The efficacy and safety of vancomycin were analyzed. Cox model and survival curve were established. Results the daily dose of vancomycin and the serum concentration of vancomycin in the adjusted group were higher than those in the unadjusted group. The bacteriological efficacy and comprehensive efficacy were also superior to those in the unadjusted group. Cox proportional risk model showed that adjusted administration regimen was the protective factor for the efficacy. No safety related risk factors were found. Conclusion the vancomycin regimen in infected patients was adjusted according to the TDM results. It is of great significance to improve the curative effect of Gram-positive bacteria infection patients.
【作者单位】：复旦大学附属华山医院抗生素研究所卫生部抗生素临床药理重点实验室;
【分类号】：R969

【相似文献】